As the Food and Drug Administration wrestles with how to regulate medical devices that rely on generative artificial intelligence to make decisions about care, it’s provisionally allowing some developers to launch their products on the market, establishing the FDA TEMPO generative AI devices pilot as a real-world testing ground for both regulators and companies.
How the FDA TEMPO Generative AI Devices Pilot Actually Works
AI products from Cadence and Limbic are among four devices recently accepted into the agency’s TEMPO pilot program that will allow digital health companies to release their products without marketing authorization. By exercising enforcement discretion, FDA allows device manufacturers to forego certain marketing requirements, such as labeling and premarket authorization, while participating in the pilot.
What Manufacturers Must Provide to Join
As of Jan. 2, 2026, FDA began accepting statements of interest from manufacturers, which must include proposed indications for use identifying the intended use to improve patient outcomes in a clinical use area from the four CMMI ACCESS model areas, the manufacturer’s name and device description, and details of any current authorizations or prior interactions related to the device.
Why the FDA TEMPO Generative AI Devices Pilot Is Tied to Medicare ACCESS
The pilot is intended to beef up the number of technologies available for the Medicare ACCESS model, an experiment in paying for technology to help beneficiaries manage chronic conditions. But it also offers the agency and companies the opportunity to experiment with AI regulation in the real world.
What Participating Manufacturers Are Expected to Collect
Manufacturers selected for the TEMPO pilot are expected to collect real-world data relating to the intended use, which they may then use to generate real-world evidence supporting a future application for full marketing authorization, meaning provisional market access under TEMPO functions as a bridge toward, rather than a replacement for, standard FDA clearance.
The Broader Regulatory Framework Behind FDA TEMPO Generative AI Devices
The TEMPO pilot arrives alongside a separate but related regulatory effort: on Aug. 18, the FDA’s Digital Health Center of Excellence published a discussion paper on “Considerations for the Regulation of Generative AI-Enabled Medical Devices,” seeking feedback on risk assessment, premarket evaluation, postmarket monitoring, and other topics specific to this technology category.
The Competency Assessment Approach FDA Is Considering
The paper discusses a potential approach to premarket evaluation built on the concept of competency assessment, inspired at a high level by how physicians are trained and evaluated, consisting of non-clinical device benchmarking and clinical confirmation to evaluate whether a GenAI-enabled medical device performs as intended before reaching patients. The paper also describes potential approaches to risk-proportionate postmarket monitoring and addresses considerations around foundation models and agentic AI systems specifically.
Why This Framework Reflects Broader Administration Priorities
“Artificial intelligence is transforming medicine, and the United States must lead in shaping how this technology is developed and used safely and responsibly,” said Acting FDA Commissioner Kyle Diamantas. This effort aligns with one of the Trump administration’s key priorities to harness AI to accelerate the delivery of innovative medical products to market, and the discussion paper supports FDA’s stated “innovation and global leadership” strategic pillar.
The Public Comment Window Still Open
The FDA encourages feedback on the discussion paper from device manufacturers, clinicians, consumers, researchers, and other interested parties, with comments due under docket FDA-2026-N-7874 on Regulations.gov by Oct. 19, 2026. Notably, the paper explicitly states it is not intended to address whether the approaches discussed fall within FDA’s existing legal authorities or would require new ones, leaving that determination for a later stage of the regulatory process.
What This FDA TEMPO Generative AI Devices Pilot Means Going Forward
With Cadence and Limbic already operating under TEMPO’s enforcement discretion while the broader discussion paper’s comment period remains open through October, the FDA appears to be pursuing regulatory learning on two parallel tracks: real-world pilot experience and formal stakeholder feedback. Given that TEMPO participants are expected to generate real-world evidence supporting eventual full marketing authorization applications, the pilot’s early cohort may effectively serve as a proving ground informing how the FDA’s eventual competency assessment framework gets applied in practice.
What to Watch Going Forward
As the Oct. 19 comment deadline approaches, industry observers will likely watch how stakeholder feedback shapes FDA’s competency assessment framework, particularly around foundation models and agentic AI systems the discussion paper specifically flags as carrying unique risks. Given that this TEMPO pilot is explicitly not intended to resolve underlying legal authority questions, this FDA TEMPO generative AI devices pilot and its parallel rulemaking process may represent only the earliest phase of a longer regulatory journey toward a formalized generative AI medical device framework.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
